Sanofi posts 7% sales growth, driven by Dupixent and new launches

French pharma major Sanofi (Euronext: SAN) reported third-quarter 2025 revenue of 12.4 billion euros ($13.2 billion), up 7% at constant exchange rates, with business earnings per share rising 13% to 2.91 euros ($3.09). The company said continued strength in its immunology and rare disease portfolios offset weaker vaccine sales.

Growth was led by a 26% surge in Dupixent (dupilumab) sales to 4.2 billion euros, marking the first time the blockbuster crossed the 4 billion euro quarterly mark. Newly launched medicines such as Altuviiio (hemophilia A) and Ayvakit (mastocytosis) also contributed strongly, lifting launch portfolio revenue 57%.

Sales in the USA rose 11%, while Europe and the rest of the world grew modestly. Vaccine revenue fell 8% to 3.4 billion euros, reflecting lower influenza sales amid increased price competition and reduced vaccination rates.